Disc Medicine (IRON) Competitors

$66.82 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$66.81 -0.01 (-0.01%)

As of 05/22/2026 04:10 PM Eastern

IRON vs. CYTK, ABVX, PRAX, KRYS, and IBRX

Should you buy Disc Medicine stock or one of its competitors? MarketBeat compares Disc Medicine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Disc Medicine include Cytokinetics (CYTK), Abivax (ABVX), Praxis Precision Medicines (PRAX), Krystal Biotech (KRYS), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.

How does Disc Medicine compare to Cytokinetics?

Disc Medicine (NASDAQ:IRON) and Cytokinetics (NASDAQ:CYTK) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Disc Medicine has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
Cytokinetics	$88.04M	108.74	-$784.96M	-$6.84	N/A

Disc Medicine has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

Disc Medicine presently has a consensus price target of $105.30, indicating a potential upside of 57.59%. Cytokinetics has a consensus price target of $99.30, indicating a potential upside of 29.06%. Given Disc Medicine's higher possible upside, analysts clearly believe Disc Medicine is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86

Disc Medicine has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
Cytokinetics	-784.02%	N/A	-52.86%

In the previous week, Cytokinetics had 5 more articles in the media than Disc Medicine. MarketBeat recorded 10 mentions for Cytokinetics and 5 mentions for Disc Medicine. Cytokinetics' average media sentiment score of 1.15 beat Disc Medicine's score of 0.60 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.7% of Disc Medicine shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by insiders. Comparatively, 2.6% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Disc Medicine beats Cytokinetics on 9 of the 16 factors compared between the two stocks.

How does Disc Medicine compare to Abivax?

Abivax (NASDAQ:ABVX) and Disc Medicine (NASDAQ:IRON) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Abivax is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

In the previous week, Abivax had 2 more articles in the media than Disc Medicine. MarketBeat recorded 7 mentions for Abivax and 5 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.60 beat Abivax's score of 0.38 indicating that Disc Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Disc Medicine	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abivax currently has a consensus price target of $137.15, suggesting a potential upside of 12.43%. Disc Medicine has a consensus price target of $105.30, suggesting a potential upside of 57.59%. Given Disc Medicine's higher possible upside, analysts plainly believe Disc Medicine is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Abivax has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

47.9% of Abivax shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Disc Medicine's return on equity of -36.94% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-146.43%	-88.69%
Disc Medicine	N/A	-36.94%	-33.88%

Summary

Disc Medicine beats Abivax on 9 of the 14 factors compared between the two stocks.

How does Disc Medicine compare to Praxis Precision Medicines?

Disc Medicine (NASDAQ:IRON) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, Disc Medicine had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 5 mentions for Disc Medicine and 3 mentions for Praxis Precision Medicines. Disc Medicine's average media sentiment score of 0.60 beat Praxis Precision Medicines' score of 0.04 indicating that Disc Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Disc Medicine has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.76, meaning that its share price is 176% more volatile than the broader market.

Disc Medicine's return on equity of -36.94% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Disc Medicine has higher earnings, but lower revenue than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
Praxis Precision Medicines	$8.55M	1,120.29	-$303.27M	-$13.37	N/A

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Disc Medicine currently has a consensus target price of $105.30, indicating a potential upside of 57.59%. Praxis Precision Medicines has a consensus target price of $592.67, indicating a potential upside of 72.51%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95

Summary

Disc Medicine beats Praxis Precision Medicines on 9 of the 15 factors compared between the two stocks.

How does Disc Medicine compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Disc Medicine (NASDAQ:IRON) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 3.8% of Disc Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Krystal Biotech currently has a consensus price target of $324.11, suggesting a potential upside of 8.24%. Disc Medicine has a consensus price target of $105.30, suggesting a potential upside of 57.59%. Given Disc Medicine's higher probable upside, analysts clearly believe Disc Medicine is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Krystal Biotech has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

Krystal Biotech has a net margin of 53.92% compared to Disc Medicine's net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Disc Medicine	N/A	-36.94%	-33.88%

In the previous week, Krystal Biotech had 1 more articles in the media than Disc Medicine. MarketBeat recorded 6 mentions for Krystal Biotech and 5 mentions for Disc Medicine. Krystal Biotech's average media sentiment score of 0.98 beat Disc Medicine's score of 0.60 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Disc Medicine	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	22.69	$204.83M	$7.48	40.03
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

Summary

Krystal Biotech beats Disc Medicine on 12 of the 14 factors compared between the two stocks.

How does Disc Medicine compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Disc Medicine (NASDAQ:IRON) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

ImmunityBio has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

Disc Medicine has lower revenue, but higher earnings than ImmunityBio. Disc Medicine is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	66.75	-$351.40M	-$0.85	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 69.5% of ImmunityBio shares are held by insiders. Comparatively, 3.8% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Disc Medicine has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Disc Medicine	N/A	-36.94%	-33.88%

In the previous week, ImmunityBio had 45 more articles in the media than Disc Medicine. MarketBeat recorded 50 mentions for ImmunityBio and 5 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.60 beat ImmunityBio's score of 0.16 indicating that Disc Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	6 Very Positive mention(s)	6 Positive mention(s)	35 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Disc Medicine	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmunityBio presently has a consensus target price of $14.20, suggesting a potential upside of 96.68%. Disc Medicine has a consensus target price of $105.30, suggesting a potential upside of 57.59%. Given ImmunityBio's higher possible upside, analysts clearly believe ImmunityBio is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Disc Medicine beats ImmunityBio on 8 of the 15 factors compared between the two stocks.

Get Disc Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRON vs. The Competition

Export

Metric	Disc Medicine	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.55B	$3.37B	$6.45B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-10.09	18.74	21.22	25.65
Price / Sales	N/A	323.98	553.92	86.28
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	3.70	7.09	10.37	7.14
Net Income	-$212.18M	$24.45M	$3.57B	$335.98M
7 Day Performance	-0.04%	5.45%	6.01%	3.56%
1 Month Performance	-2.95%	2.43%	3.52%	2.54%
1 Year Performance	41.06%	62.98%	34.13%	35.05%

Disc Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRON Disc Medicine	2.3624 of 5 stars	$66.82 flat	$105.30 +57.6%	+41.1%	$2.55B	N/A	N/A	30
CYTK Cytokinetics	2.9512 of 5 stars	$76.45 +1.7%	$99.30 +29.9%	+151.9%	$9.51B	$88.04M	N/A	250	Positive News
ABVX Abivax	2.9521 of 5 stars	$113.73 +0.2%	$137.15 +20.6%	+2,051.5%	$9.06B	N/A	N/A	61	Earnings Report Analyst Upgrade Gap Up
PRAX Praxis Precision Medicines	3.0829 of 5 stars	$320.61 +0.0%	$592.67 +84.9%	+814.9%	$8.94B	$8.55M	N/A	110
KRYS Krystal Biotech	3.0384 of 5 stars	$293.30 +0.5%	$324.11 +10.5%	+139.5%	$8.65B	$389.13M	39.21	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRON) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Disc Medicine (IRON) Competitors

IRON vs. CYTK, ABVX, PRAX, KRYS, and IBRX

How does Disc Medicine compare to Cytokinetics?

Summary

How does Disc Medicine compare to Abivax?

Summary

How does Disc Medicine compare to Praxis Precision Medicines?

Summary

How does Disc Medicine compare to Krystal Biotech?

Summary

How does Disc Medicine compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRON vs. The Competition

Disc Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Disc Medicine (IRON) Competitors

IRON vs. CYTK, ABVX, PRAX, KRYS, and IBRX

How does Disc Medicine compare to Cytokinetics?

Which has stronger earnings & valuation, IRON or CYTK?

Which has more risk & volatility, IRON or CYTK?

Do analysts rate IRON or CYTK?

Is IRON or CYTK more profitable?

Does the media prefer IRON or CYTK?

Do insiders and institutionals have more ownership in IRON or CYTK?

Summary

How does Disc Medicine compare to Abivax?

Which has stronger valuation and earnings, ABVX or IRON?

Does the media favor ABVX or IRON?

Do analysts recommend ABVX or IRON?

Which has more volatility and risk, ABVX or IRON?

Do institutionals and insiders hold more shares of ABVX or IRON?

Is ABVX or IRON more profitable?

Summary

How does Disc Medicine compare to Praxis Precision Medicines?

Does the media prefer IRON or PRAX?

Which has more risk & volatility, IRON or PRAX?

Is IRON or PRAX more profitable?

Which has preferable earnings & valuation, IRON or PRAX?

Do institutionals & insiders have more ownership in IRON or PRAX?

Do analysts recommend IRON or PRAX?

Summary

How does Disc Medicine compare to Krystal Biotech?

Do insiders & institutionals hold more shares of KRYS or IRON?

Do analysts rate KRYS or IRON?

Which has more volatility and risk, KRYS or IRON?

Is KRYS or IRON more profitable?

Does the media favor KRYS or IRON?

Which has better valuation and earnings, KRYS or IRON?

Summary

How does Disc Medicine compare to ImmunityBio?

Which has more volatility & risk, IBRX or IRON?

Which has higher earnings & valuation, IBRX or IRON?

Do insiders and institutionals hold more shares of IBRX or IRON?

Is IBRX or IRON more profitable?

Does the media favor IBRX or IRON?

Do analysts rate IBRX or IRON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRON vs. The Competition

Disc Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools